Management and Outcome of Scorpion Sting in Children

NCT ID: NCT06615440

Last Updated: 2024-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-30

Study Completion Date

2026-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the clinical characteristics of children with scorpion sting and implement guidelines for management of those children and observe the outcome

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Scorpion envenomation is a severe,sometimes fatal medical condition especially in children .Worldwide,there are more than 1.2 million scorpion stings each year,mostly in tropical and subtropical regions.Every year,more than 420,000 snake bite,scorpion sting and spider bite incidents occur in the Middle East and North Africa (MENA).In the region of Assiut,in the South of Egypt,the annual incidence and mortality by scorpion stings has been reported to be 88 and 5.5 per 100,000 inhabitants.There are 1500 sub species of scorpions in the globe,and 50 of those have venom that is harmful to humans.The most toxic scorpion families are the Buthidae family.The MENA region is home to 27 species of scorpions from three families:theButhidae,Hemiscorpiidae,and Scorpionidae.Significant morbidity and mortality are caused by scorpion stings .In addition to local effectslikeredness,pain,burning,and swelling,scorpion venom exhibits variability among sub species and has a complex structure made up of neurotoxic proteins,salts,acidic proteins,and organic compounds.These components can cause neurological,cardiovascular,hematologic,and renal side effects.Because scorpion venoms are complex mixtures of several toxins,including cardiotoxins,nephrotoxins,hemolytictoxins,and neurotoxins,there is a possible danger of developing severe and frequently deadly clinical consequences.Heart failure and pulmonary edema are the main causes of mortality .As regards management of scorpion sting early antivenom treatment is recommended but its value remains controversial as it may cause anaphylactic reactions .Furthermore the majority of cases need supportive treatment to alleviate the cardiovascular effect.Cardiovascular symptoms respond well to vasodilators such as alpha-1blockers like prazosin.Prazosinis considered a physiological and pharmacological antidote to scorpion venom action.It antagonizes the after-effects of venom-liberated catecholamines.Since the use of prazosin with antivenom the recovery from scorpion sting has been hastened and mortality rate has been reduced from 30% to 1%.Uptill now there are no guidlines implemented at our hospital for the management of scorpion sting so that our study will aim at implementing guidelines for management of children with scorpion sting and observe the outcome of those children.The guidelines used are those recommended from the Egyptian ministry of health and Population with the addition of prazosin as many studies have concluded the benefits of prazosin

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scorpion Stings

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alpha blocker

prazosin will be given to all children with systemic manifestations (orally or by nasogastric tube) at a dose of 30 μg/kg/dose;first repeat dose at 3 h followed by every 6 h till recovery. All patients will be monitored for clinical improvement with vital signs

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- All children under 18 years with definite history of scorpion sting

Exclusion Criteria

* Children with no definite history of sting or more than 18 years
Minimum Eligible Age

0 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mahmoud Hamdy Abdelaziz Sayed

Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children hospital Assiut University

Asyut, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mahmoud Mahmoudhamdi

Role: CONTACT

+201002033862

Ghada Elsedfy, Prof

Role: CONTACT

+201111985154

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ghada Elsedfy, Prof

Role: primary

01111985154

References

Explore related publications, articles, or registry entries linked to this study.

WorldHealthOrganization.WHOExpertCommitteeonBiologicalStandardization, sixty-seventhreport.Licence:CCBY-NC-SA3.0IGO.Geneva;2017.Available: https://www.who.int/publications/i/item/9789241210133

Reference Type BACKGROUND

Rajniti Prasad et al. Indian J Pediatr. 2011 May.https://link.springer.com/article/10.1007/s12098-010-0265-0

Reference Type BACKGROUND

Kumar,Rakesh.AnupdateonepidemiologyandmanagementpracticesofScorpio nenvenomationinIndia.*JournalofFamilyMedicineandPrimaryCare*.11(9),493 2- 4935,September2022.DOI:10.4103/jfmpc.jfmpc_2300_2

Reference Type BACKGROUND

Mohamad IL, Elsayh KI, Mohammad HA, Saad K, Zahran AM, Abdallah AM, Tawfeek MS, Monazea EM. Clinical characteristics and outcome of children stung by scorpion. Eur J Pediatr. 2014 Jun;173(6):815-8. doi: 10.1007/s00431-013-2244-8. Epub 2014 Jan 3.

Reference Type BACKGROUND
PMID: 24384790 (View on PubMed)

FarghalyWM,AliFA(1999)Aclinicalandneurophysiologicalstudyofscorpion envenomationinAssiut,UpperEgypt.ActaPaediatr88(3):290-294.

Reference Type BACKGROUND

Bawaskar HS, Bawaskar PH. Clinical profile of severe scorpion envenomation in children at rural setting. Indian Pediatr. 2003 Nov;40(11):1072-5.

Reference Type BACKGROUND
PMID: 14660839 (View on PubMed)

https://scholar.google.com/scholar_lookup?journal=Int.+J.+Bioinform.+Biomed.+Eng.&title=Scorpion+sting+in+different+regions+of+Sudan:+epidemiological+and+clinical+survey+among+university+students&author=N.+Ali&author=N.+O+M+Ali&publication_year=2015&

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Management of scorpion sting

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Ketorolac in Palatoplasty
NCT04771156 RECRUITING PHASE4
Citicoline as Neuroprotector in Preterm
NCT03966170 RECRUITING PHASE3